Tissue Engineered Cartilage, by Christine Davis
- 1 Articular Cartilage Damage
- 2 Cartilage Repair Issues
- 3 History of Advances in Cartilage Repair
- 4 Cartilage Repair Techniques 
- 5 New or Specific Tissue Engineering Techniques
- 6 New and Relevant Findings
- 7 References
Articular Cartilage Damage
Articular cartilage is the type of cartilage found between joints to reduce friction and act as a shock absorber . Because this cartilage gets so much wear, some deterioration is inevitable. However, excessive deterioration caused by sports injuries, overuse, birth abnormalities, or osteoarthritis can be debilitating. Because cartilage is an avascular area, blood cannot bring nutrients, enzymes, or proteins to injured cartilage. Over 6 million people visit the hospital for cartilage damage every year, and osteoarthritis, or arthritis due to the degradation of articular cartilage, affects 33% of U.S. adults 65 years of age or older . Health care costs related to cartilage damage are staggering. The total annual cost of living with osteoarthritis is $5,700/year per patient . Job-related osteoarthritis costs are estimated at $3.4-$13.2 billion/year. Additionally, hospital related costs for total knee and hip replacements are estimated at $28.5 billion/year and $13.7 billion/year each. These statistics are merely for osteoarthritis and knee/hip replacements; they do not take into consideration various arthroscopic surgeries for cartilage debridement, tear suturing, etc., signifying that he potential market for an effective engineered cartilage is large and undertapped. At the moment, we can repair cartilage but not restore it. The repairs have varying levels of efficiency and varying lifespans. The goal is to one day be able to completely regrow new cartilage that perfectly matches the patient's needs, in size and immunocompatibility.
Cartilage Repair Issues
Currently, scientists can easily grow chondrocytes, the cells that make up cartilage, in a lab. The problem is with creating strong enough cartilage to withstand the immense pressures in vivo and with making sure the chondrocytes stay where they are needed. There is also a lack of research showing the effects of time on artificial cartilage function. The avascular nature of the cartilage means that any implanted cartilage must have all of the necessary factors to thrive, particularly in a low oxygen environment; scientists cannot rely on blood vessels to bring oxygen, proteins, enzymes, growth factors, or any other building block. Additionally, while many traditional treatments for cartilage damage do regrow cartilage, the cartilage grown is the wrong type. The type of cartilage needed for articular cartilage is called hyaline cartilage, and it is made of 5% chondrocytes and 95% extracellular matrix, mostly collagen and proteoglycans . The type of cartilage formed by typical treatments is often a hybrid of hyaline cartilage and fibrocartilage, which has weaker mechanical properties.
History of Advances in Cartilage Repair
- 1965 : Chondrocytes first isolated and grown 
- 1984 : Lars Petersen treatments of patellar hole drilled in rabbit knees with autologous chondrocytes 
- 1987 : Sweden ACI (autologous chondrocyte implantation), 1st human trial 
- 1994 : Brittberg paper shows majority excellent or good ACI results of 23 patients, cartilage has hyaline-type appearance 
- 1995 : Autologous cartilage implantation begins to be widely used
- 1997 : Carticel® by Genzyme approved by FDA for autologous chondrocyte implantation in knees as a second resort- has slight overgrowth problems, requires 2 surgeries (remove chondrocytes, send to Genzyme, re-implant with a periosteal patch from lower leg), not for patients with osteoarthritis 
- 2002 : Mitek Worldwide (Johnson & Johnson) and Verigen start MACI® clinical trials in the United States. MACI is similar to Carticel, but instead of a periosteal patch, a membrane of cow collagen is used. MACI allows for osteoarthritic patients and patients with large cartilage tears. 
- 2002-2010: Clinical trials, testing different hydrogels and matrices for ACI
- 2010: NeoCart starts clinical trials 
- 2012: MACI (Sanofi now), NeoCart proven to be superior to microfracture 
- 2014: Columbia University researchers grow human cartilage from mesenchymal stem cells 
- 2015: Columbia University researchers discover possible new stem cells that differentiate into chondrocytes 
Cartilage Repair Techniques 
- Microfracture: small holes are created in the bone until it bleeds (cartilage is avascular, so this is the only way to introduce bleeding)- this forms a matrix of blood clots that cartilage can begin to grow on . Most of this cartilage is fibrocartilage, however, and it is subpar.
- Osteochondral Autograft Transplantation (Mosaicplasty): a “plug” of cartilage and bone is removed from one part of the knee and placed in the damaged part
- Osteochondral Allograft Transplantation: “plugs” taken from deceased donor if the transplantation site is large or if the entire area is compromised
- Autologous Chondrocyte Implantation (ACI): chondrocytes arthroscopically removed, grown in culture outside the body, and then reimplanted underneath a periosteum flap (flap made of tissue covering bone)
- Cell-Based Cartilage Resurfacing: experimental treatments using autologous cells to grow new cartilage (ex. NeoCart, though still phase 3) - similar to ACI but the cells are implanted in a scaffold before reinsertion and incubated in a container than mimics cartilage formation conditions (low oxygen, varied mechanical forces)
New or Specific Tissue Engineering Techniques
ACI-derived treatments center around injecting chondrocyte cells into patients. These cells have been previously harvested from the patients and grown in culture in a lab before being sent back to be reimplanted. The downside of these treatments is that they require two separate surgeries and some types have restrictions .
- Carticel (Genzyme): cartilage cells harvested from patient, sent to Genzyme, where they are grown and sent back. The cells are then injected into a fabricated pocket on the bone made of periosteal tissue from the lower limbs. This is a second option for patients who have tried more traditional methods, and it is not approved for use in osteoarthritic patients .
- MACI (Sanofi): Similar to Carticel, cartilage cells harvested from patient, sent to Sanofi, where they are grown and sent back, but instead of a periosteal patch, a membrane of cow collagen is used. MACI allows for osteoarthritic patients and patients with large cartilage tears .
- NeoCart (Histogenics): cartilage cells harvested from patient, sent to Histogenics, where they are placed in a collagen scaffold and put in a proprietary incubator, which delivers various amounts of mechanical stress and oxygen levels .
Mesenchymal Stem Cell Treatments
MSC-derived treatments are important, because while autologous chondrocyte use via ACI is an effective treatment, articular cartilage repair requires many cells, sometimes too many to be harvested from other parts of the body. MSCs from bone marrow are the typical choice, as they are easily harvested, have good chondrogenic potential, and are most effective in vivo. To induce chondrogenesis, transforming growth factors, insulin-like growth factos, bone morphogenic proteins, fibroblast factors, varying hydrostatic pressure, varying cyclic compression, etc. can all be used in varying ways and amounts. Going forward, scientists seek to optimize culture conditions for MSC treatments, and to understand the differentiation mechanisms for MSCs. Most of the MSC-based treatments are still in clinical trials, but a few are in the final stages .
- Chondrogen (Osiris): injections of chondrogen, which contains mesenchymal stem cells, are in the beginning phases of testing- they have been found to decrease the amount of osteoarthritis bone degeneration and pain .
- Cartiform (Osiris): cartilage mesh made of 3D hyaline cartilage with the necessary growth factors to stimulate MSC activity. MSC activity is passively stimulated (does not contain stem cells when implanted). Cartiform is in stage 3 clinical trials .
Embryonic Stem Cell Treatments
ESC-derived treatments are nowhere near clinical trials, as ESC experimentation was tied up by political red tape for a long time. However, researchers have found that ESCs are able to form new cartilage with or without scaffolds. In the future, scientists will seek to improve differentiation efficiency and load-bearing aspects of the scaffolds .
New and Relevant Findings
2014: Columbia University researchers published an article called "Large, Stratified, and Mechanically Functional Human Cartilage Grown In Vitro by Mesenchymal Condensation" in Proceedings of the National Academy of Sciences of the United States of America on April 28th, 2014 . The article presented the labs groundbreaking procedure to induce adult MSCs to form human cartilage for the first time. So far, all treatments for cartilage damage using MSCs have merely stimulated, induced, or injected MSCs as treatment. This finding opens the door to potentially using MSCs to actually grow cartilage to implant in humans. Previous attempted to induce adult MSCs to form human cartilage added adult MSCs to hydrogels and culturing them with growth factors, nutrients, and mechanical loading procedures. However, this attempt nearly always produced mechanically weak cartilage. The researchers from Columbia decided to try to mimic the body's environment at the time this cartilage is biologically formed, so they first caused the MSCs to undergo a condensation into cellular bodies. The findings from this procedure were that, for the first time, the strength and lubrication of the cartilage pieces was very close to that of real cartilage. This is an exciting discovery because it could lead to a future ability to be able to differentiate MSCs into cartilage.
Columbia University researchers form human cartilage from stem cells for the first time ever: <"https://www.youtube.com/embed/sJJ5920pqyQ">
2015: Columbia University researchers published an article called "Gremlin1 Identifies a Skeletal Stem Cell With Bone, Cartilage, and Reticular Stromal Potential" in Cell on January 15th, 2015 . The article presented the prolific lab's findings of a new type of stem cell in mice that differentiates into bone and cartilage, called an osteochondroreticular stem cell, or OSC. It was previously believed that MSCs differentiated into bone and cartilage, but the mechanism was not known; MSC involvement could still be possible, or MSCs and OSCs could be different differentiations from the same line. Mice and humans have very similar bone-forming pathways, so these stem cells will likely be found in humans as well. After adulthood, OSCs only activate upon injury to bone or cartilage; by learning to stimulate the differentiation of OSCs, scientists may be able to cause cartilage regeneration without any injections or in vitro culturing. This essentially complicates all previous research and methods, because if MSCs do not differentiate into cartilage, how have all of the other treatments been working? Much more research is needed to determine the implications of this.
-  Zhang, Lijie, Jerry Hu, and Kyriacos A. Athanasiou. “The Role of Tissue Engineering in Articular Cartilage Repair and Regeneration.” Critical reviews in biomedical engineering 37.1-2 (2009): 1–57. Print.
-  "Osteoarthritis." Centers for Disease Control and Prevention. Centers for Disease Control and Prevention, 16 May 2014. Web. 15 Feb. 2015.
-  Smith, Blair, Connie Li, Daniel Solomon, Matthew Whitson, Stephanie Chang. "Cartilage Repair History." Shoulder Repair for the Competitive Athlete. Brown University, 2 May 2004. Web. 15 Feb. 2015.
-  Peterson, Lars, Olle Issakson, Claes Ohlsson, Anders Nilsson, Anders Lindahl, and Mats Brittberg. "Treatment of Deep Cartilage Defects in the Knee with Autologous Chondrocyte Transplantation — NEJM." New England Journal of Medicine. New England Journal of Medicine, 6 Oct. 1994. Web. 15 Feb. 2015.
-  Genzyme Corporation. "Carticel (Autologous Cultured Chondrocytes)." (n.d.): n. pag. 2007. Web. 15 Feb. 2015.
-  Behrens, P., et al. "[New Therapy Procedure for Localized Cartilage Defects. Encouraging Results with Autologous Chondrocyte Implantation]." MMW, Fortschritte der Medizin 141.45 (1999): 49-51.
-  "NeoCart." Histogenics. Histogenics, n.d. Web. 15 Feb. 2015.
-  "Sanofi Biosurgery Product MACI Demonstrates Statistically Significant Clinical Outcomes Compared to Microfracture." Sanofi Press Releases. Sanofi-Aventis US, 12 July 2012. Web. 15 Feb. 2015.
-  Bhumiratana, Sarindr, et al. "Large, Stratified, and Mechanically Functional Human Cartilage Grown in Vitro by Mesenchymal Condensation." Proceedings of the National Academy of Sciences 111.19 (2014): 6940-5.
-  Worthley, D. L., M. Churchill, J. T. Compton, Y. Taylor, S. Mukherjee, and T. C. Wang. "Gremlin1 Identifies a Skeletal Stem Cell with Bone, Cartilage, and Reticular Stromal Potential." Cell 160.1-2 (2015): 269-84. Web. 15 Feb. 2015.
-  Osiris. "Chondrogen." Therapeutics. Osiris Therapeutics, n.d. Web. 15 Feb. 2015.
-  Osiris. "Cartiform." Therapeutics. Osiris Therapeutics, n.d. Web. 15 Feb. 2015.
-  Healthy Cartilage vs Arthritic Cartilage. Digital image. Osteoarthritis. Drugs.com, n.d. Web. 15 Feb. 2015.
-  3 Types of Cartilage. Digital image. Human Biological Science. Science1437- WestOne Services, n.d. Web. 15 Feb. 2015.
-  NeoCart Proprietary Steps. Digital image. Histogenics. Histogenics, n.d. Web. 15 Feb. 2015.